Search results for "Nous"

showing 10 items of 2193 documents

The Effects of Prostaglandin E-1 in Patients with Intermittent Claudication

2006

Aim of the study is to evaluate the effects of Prostaglandin E-1 (PGE-1) in patients with peripheral arterial disease (PAD) at the 2nd b stage Fontaines classification. The study, controlled, single blinded, enrolled 123 patients with intermittent claudication that were randomised in two groups; the first group received a treatment with PGE-1 while the second one received a pentoxifylline-buflomedil association by venous infusion. We evaluated: Pain Free Walking Distance (PFWD), Maximum Walking Distance (MWD), Rest Flow (RF), Peak Flow (PF), Basal (BVR) and Minimal Vascular Resistance (MVR) with a strain gauge plethysmograph, Resting Flow (RF), Peak Flow (PF), time to reach the Peak Flow (t…

AdultMalemedicine.medical_specialtyPyrrolidinesVasodilator AgentsProstaglandinHemodynamicsWalkingSeverity of Illness IndexMicrocirculationchemistry.chemical_compoundInternal medicineLaser-Doppler FlowmetrymedicineHumansPlethysmographAlprostadilPentoxifyllineInfusions IntravenousAgedPharmacologybusiness.industryHematologyGeneral MedicineIntermittent ClaudicationMiddle AgedLaser Doppler velocimetryIntermittent claudicationSurgeryPeripheralPlethysmographyDrug CombinationsTreatment Outcomemedicine.anatomical_structurechemistryRegional Blood FlowExercise TestVascular resistanceCardiologyMolecular MedicineFemaleVascular Resistancemedicine.symptomCardiology and Cardiovascular MedicinebusinessCardiovascular & Hematological Disorders-Drug Targets
researchProduct

Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis

2014

Background— Dabigatran and warfarin have been compared for the treatment of acute venous thromboembolism (VTE) in a previous trial. We undertook this study to extend those findings. Methods and Results— In a randomized, double-blind, double-dummy trial of 2589 patients with acute VTE treated with low-molecular-weight or unfractionated heparin for 5 to 11 days, we compared dabigatran 150 mg twice daily with warfarin. The primary outcome, recurrent symptomatic, objectively confirmed VTE and related deaths during 6 months of treatment occurred in 30 of the 1279 dabigatran patients (2.3%) compared with 28 of the 1289 warfarin patients (2.2%; hazard ratio, 1.08; 95% confidence interval [CI], 0.…

AdultMalemedicine.medical_specialtyRE-COVER IIrecurrenceAntagonists & inhibitorsAdolescentvenous thromboembolismAntithrombinsDabigatranYoung AdultDouble-Blind MethodRisk FactorsPhysiology (medical)Internal medicinemedicineHumansdabigatrancardiovascular diseasesantagonists & inhibitorAgedacute venous thromboembolismHeparinbusiness.industryWarfarinFollow up studiesAnticoagulantsantagonists & inhibitors; hemorrhage; recurrence; thrombin; venous thromboembolism; warfarinHeparinHeparin Low-Molecular-WeightMiddle AgedthrombinSettore MED/11 - Malattie Dell'Apparato CardiovascolarewarfarinHeparin.low molecular weightPooled analysisAnesthesiaAcute Diseasebeta-AlanineBenzimidazolesFemaledabigatran; warfarin; acute venous thromboembolism; RE-COVER IIhemorrhageCardiology and Cardiovascular MedicinebusinessVenous thromboembolismFollow-Up Studiesmedicine.drug
researchProduct

Oral high-dose sucrosomial iron vs intravenous iron in sideropenic anemia patients intolerant/refractory to iron sulfate: a multicentric randomized s…

2020

AbstractIron deficiency anemia is among the most frequent causes of disability. Intravenous iron is the quickest way to correct iron deficiency, bypassing the bottleneck of iron intestinal absorption, the only true mechanism of iron balance regulation in human body. Intravenous iron administration is suggested in patients who are refractory/intolerant to oral iron sulfate. However, the intravenous way of iron administration requires several precautions; as the in-hospital administration requires a resuscitation service, as imposed in Europe by the European Medicine Agency, it is very expensive and negatively affects patient’s perceived quality of life. A new oral iron formulation, Sucrosomi…

AdultMalemedicine.medical_specialtyResuscitationIntravenous sodium ferrigluconateAnemiaCost-Benefit AnalysisHigh dosesAdministration OralHigh dose030204 cardiovascular system & hematologyGastroenterologyFerric CompoundsIntestinal absorption03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRefractoryInternal medicineOral Sucrosomial ironMedicineHumans030212 general & internal medicineFerrous CompoundsProspective StudiesAgedAged 80 and overHematologyAnemia Iron-Deficiencybusiness.industryHematologyGeneral MedicineIron deficiencyMiddle Agedmedicine.diseaseIron sulfatechemistryIron-deficiency anemiaIron deficiency anemiaHematinicsAdministration IntravenousFemaleOriginal ArticleRefractoriness/intolerance to oral iron sulfatebusiness
researchProduct

Bone Marrow Concentrate and Bovine Bone Mineral for Sinus Floor Augmentation

2011

Purpose: The purpose of this work was to evaluate the potential of substituting autogenous bone (AB) by bone marrow aspirate concentrate (BMAC). Both AB and BMAC were tested in combination with a bovine bone mineral (BBM) for their ability of new bone formation (NBF) in a multicentric, randomized, controlled, clinical and histological noninferiority trial.Materials and Methods: Forty-five severely atrophied maxillary sinus from 26 patients were evaluated in a partial cross-over design. As test arm, 34 sinus of 25 patients were augmented with BBM and BMAC containing mesenchymal stem cells. Eleven control sinus from 11 patients were augmented with a mixture of 70% BBM and 30% AB. Biopsies wer…

AdultMalemedicine.medical_specialtySinus Floor AugmentationOSTEOGENIC DIFFERENTIATIONBone RegenerationMaxillary sinusBiomedical EngineeringSinus Floor AugmentationBioengineeringBiochemistryMAXILLARY SINUSlaw.inventionMESENCHYMAL STEM-CELLSBIO-OSSBiomaterialsRandomized controlled trialTISSUE-ENGINEERED BONEBone MarrowOsteogenesislawmedicineAnimalsHumansSingle-Blind MethodSinus (anatomy)AgedIMPLANT PLACEMENTHYDROXYAPATITE CERAMICSBone TransplantationIntention-to-treat analysisPOROUS HYDROXYAPATITEbusiness.industryIN-VITROMiddle AgedSurgeryAUTOGENOUS BONEImplant placementBovine bonemedicine.anatomical_structureBone SubstitutesCattleFemaleBone marrowbusinessTissue Engineering. Part A
researchProduct

Acute symptomatic seizures in cerebral venous thrombosis

2020

© 2020 American Academy of Neurology

AdultMalemedicine.medical_specialtySubarachnoid hemorrhageInfarction030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineModified Rankin ScaleRisk FactorsSeizuresInternal medicinemedicineHumans030212 general & internal medicineStrokeIntracerebral hemorrhageVenous Thrombosisbusiness.industrycerebral venous thrombosisSymptomatic seizuresOdds ratioMiddle Agedmedicine.diseaseThrombosisCerebral Veins3. Good healthVenous thrombosisAnesthesiaSettore MED/26 - NeurologiaFemaleNeurology (clinical)Intracranial Thrombosisbusiness030217 neurology & neurosurgery
researchProduct

Management and Outcomes of Patients with Isolated Superficial Vein Thrombosis under Real Life Conditions (INSIGHTS-SVT).

2021

Objective Management and outcomes of superficial vein thrombosis (SVT) are highly variable and not well described. Therefore, the INvestigating SIGnificant Health TrendS in the management of SVT (INSIGHTS-SVT) study collected prospective data under real life conditions. Methods Prospective observational study of objectively confirmed acute isolated SVT. The primary outcome was a composite of symptomatic deep vein thrombosis (DVT), pulmonary embolism (PE), and extension or recurrence of SVT at three months. The primary safety outcome was clinically relevant bleeding. Results A total of 1 150 patients were included (mean age 60.2 ± 14.7 years; 64.9% women; mean BMI 29.4 ± 6.3 kg/m2). SVT was …

AdultMalemedicine.medical_specialtySuperficial vein thrombosismedicine.drug_classDeep veinLow molecular weight heparinHemorrhage030204 cardiovascular system & hematology030230 surgeryFondaparinuxVaricose Veins03 medical and health sciences0302 clinical medicineRecurrenceRisk FactorsmedicineHumansProspective StudiesAgedAged 80 and overVenous Thrombosisbusiness.industryHazard ratioLeg UlcerAnticoagulantsHeparin Low-Molecular-WeightMiddle Agedmedicine.diseaseThrombosisPulmonary embolismSurgeryVenous thrombosismedicine.anatomical_structureTreatment OutcomeFondaparinuxLower ExtremityVenous InsufficiencySurgeryFemaleCardiology and Cardiovascular MedicinebusinessPulmonary EmbolismStockings Compressionmedicine.drugFactor Xa InhibitorsEuropean journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery
researchProduct

Calf muscle pump impairment and delayed healing of venous leg ulcers: Air plethysmographic findings

2007

There is a need for a diagnostic tool to predict clinical outcome of venous leg ulcer patients, as the prognosis of healing based on clinical data alone has not appeared to be satisfactory. Air plethysmographic assessment of calf muscle pump was performed in the supine and upright position in 129 patients with active ulcers on their legs. All patients were managed in a specialized leg ulcer clinic. Results of air plethysmography were compared to clinical data and time of healing of ulcers. Muscle pump failure was found in 42.6% of extremities (supine position, 33.3%; upright, 22.5%; both, 12.4%). Patients with insufficient pump were older, and their ulcers were larger. Failure of pump was f…

AdultMalemedicine.medical_specialtySupine positionDermatologyVenous leg ulcerVaricose UlcerRisk Factorsleg ulcermedicineHumansPlethysmographVaricose UlcerMuscle SkeletalAgedAged 80 and overWound Healingplethysmographybusiness.industryCalf muscle pumpcalf muscle pumpGeneral MedicineMiddle AgedPrognosismedicine.diseasedigestive system diseasesSurgeryLeg ulcerLower ExtremityVenous InsufficiencyFemalemedicine.symptombusinessDelayed healingMuscle ContractionMuscle contractionThe Journal of Dermatology
researchProduct

Endoscopic subfascial sectioning of incompetent perforating veins in treatment of primary varicosis

1992

Subfascial elimination of incompetent perforating veins is the most effective therapeutic principle in the treatment of trophic skin disorders associated with varicosis. A recently developed endoscopic technique allows accurate sectioning of perforating veins with direct observation of the veins and minor trauma. From November 1986 to July 1991 endoscopic sectioning of perforating veins was performed in 72 patients (103 legs). The most frequently transected perforating veins were Cockett's veins (n = 219), 24 cm perforating veins (n = 83), and Boyd's perforating veins (n = 82). Postoperative delayed wound healing was observed in 3 (2.9%) legs with pronounced trophic skin disorders in the lo…

AdultMalemedicine.medical_specialtySural nervePerforator veinVaricose VeinsPostoperative ComplicationsmedicineHumansAgedAged 80 and overDysesthesiaVarixRupture Spontaneousbusiness.industryEndoscopyAnatomyMiddle AgedVascular surgeryFasciotomySurgerySaphenous nerveVenous InsufficiencyFemaleSurgerymedicine.symptomVaricesbusinessVascular Surgical ProceduresFollow-Up StudiesAbdominal surgeryWorld Journal of Surgery
researchProduct

Usefulness of Thrombophilia Testing in Venous Thromboembolic Disease

2012

Information on thrombophilia risk factors for patients with upper extremity deep vein thrombosis (UEDVT) is limited. The genetic, acquired, and coagulation risk factors of an acute episode of lower EDVT (LEDVT) or UEDVT, either isolated or associated with pulmonary embolism (PE), were studied.A total of 4503 patients participated in a thrombophilia study. Odds ratio (OR) and 95% confidence intervals (CIs) were calculated.Mean age of the participants was 55 ± 19 years. The risk of LEDVT or UEDVT, isolated or associated with PE, was calculated according to thrombophilia factors. We found association between LEDVT and factor V Leiden ([FVL]; OR: 1.8; 95% CI 1.4-2.4) and resistance to activated…

AdultMalemedicine.medical_specialtyThrombophiliaRisk FactorsInternal medicinemedicineFactor V LeidenHumansThrombophiliaUpper Extremity Deep Vein ThrombosisRegistriesActivated Protein C ResistanceAgedVenous Thrombosisbusiness.industryAge FactorsFactor VVenous ThromboembolismHematologyGeneral MedicineOdds ratioMiddle Agedmedicine.diseaseConfidence intervalSurgeryPulmonary embolismProthrombin G20210AFemaleProthrombinbusinessProtein CFollow-Up Studiesmedicine.drugClinical and Applied Thrombosis/Hemostasis
researchProduct

Clopidogrel and aspirin in the prevention of thromboembolic complications after mechanical aortic valve replacement (CAPTA)

2003

Axel Schlitt*, Ralf S. von Bardeleben, Anne Ehrlich, Antje Eimermacher, Dirk Peetz, Manfred Dahm, Hans J. Rupprecht Department of Medicine II, Johannes Gutenberg-University Mainz, Langenbeckstr. 1, 55131 Mainz, Germany Coordination Center for Clinical Studies, Johannes Gutenberg-University Mainz, Mainz, Germany Clinic for Clinical Chemistry and Laboratory Medicine, Johannes Gutenberg-University Mainz, Mainz, Germany Department of Cardiothoracic and Vascular Surgery, Johannes Gutenberg-University Mainz, Mainz, Germany

AdultMalemedicine.medical_specialtyTiclopidineTreatment outcomeAdministration OralHemorrhagePilot ProjectsValvula aorticaProstaglandin-Endoperoxide SynthaseThromboembolismmedicineHumansOral anticoagulationAgedAspirinAspirinbusiness.industryHematologyMiddle AgedClopidogrelClopidogrelSurgeryTreatment OutcomeAortic ValveHeart Valve ProsthesisAortic valve surgeryPhenprocoumonDrug Therapy CombinationFemalebusinessVenous diseasemedicine.drugThrombosis Research
researchProduct